product_xtreme_header.jpg

Products

back.png

THREE CUTTING EDGE DEVICES


 

NovaCross™

The NovaCross™ is Nitiloop’s first-generation product. It recently completed a pivotal study and received FDA and CE clearance. The NovaCross™ consists of a nitinol scaffold, that while deployed, supports and centers a standard guidewire. When the scaffold is closed, the microcatheter can be further advanced.

NovaCross™ Xtreme

The NovaCross™ Xtreme is Nitiloop’s flagship product. It is composed of a nitinol scaffold that while deployed supports both the guidewire and a crossing microcatheter that advances independently. The NovaCross™ Xtreme is FDA approved. 
 

NovaCross™ BTK

The NovaCross™ Below-the-Knee (BTK) is a modified version of the NovaCross™ Xtreme designed to reach the lower limbs in an antegrade or contra-lateral approach. The NovaCross™ BTK is CE approved.

products7.jpg

 NITILOOP'S PRODUCT LINE

NovaCross™

Coronary and peripheral applications 

For difficult to treat coronary and peripheral lesions 

Coronary and peripheral applications 

For very challenging coronary and peripheral CTO procedures 

Peripheral applications
Below-the-Knee

For challenging lesions in the peripheral vasculature

NovaCross™ Xtreme

NovaCross™ BTK

back2.png

Dr. William Nicholson

Wellspan Hospital

York, PA, USA

The NovaCross™ is a significant new addition to our CTO toolbox for tackling lesions. It improves our antegrade success rate while minimizing the risk of perforation. The device is simple and safe and can be easily adopted by either high-volume or low-volume cath lab clinicians.

Dr. Simon Walsh,
Belfast Trust Hospital
United Kingdom

The NovaCross device has now completed evaluation in first-in-human and a pivotal FDA approval trial. The data confirm that the device is safe and efficacious, facilitating proximal cap crossing and success with antegrade wiring in complex lesions. The NovaCross gives added support for wiring and does not require added training for physician use.

© 2020  all rights reserved to Nitiloop.